Nebenwirkungen · Jemperli
JEMPERLI 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-145341 · Präparat HOS-099336
In patients with advanced or recurrent solid tumours (N = 605), the most common adverse reactions (> 10 %) were anaemia (28.6 %), diarrhoea (26.0 %), nausea (25.8 %), vomiting (19.0 %), arthralgia (17.0 %), pruritus (14.2 %), rash (13.2 %), pyrexia (12.4 %), aspartate aminotransferase increased (11.2 %) and hypothyroidism (11.2 %). JEMPERLI was permanently discontinued due to adverse reactions in 38 (6.3 %) patients; most of them were immune-related events. Adverse reactions were serious in 11.2 % of patients; most serious adverse reactions were immune-related adverse reactions (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T11:00:00Z · SHA-256 c9cfea3ac27190f9161acc3184a04c8f1d0df0ea11733d3f3f64b1b633b93895 · Passage f1daa1254ce0d61f5bea1d6b5820320012460f894450d8a43624ab23ba41a6f6 · Zeichen 676–1279 im Abschnitt